Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
Titel:
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
Auteur:
Gupta, Shilpa Loriot, Yohann Van der Heijden, Michiel S Bedke, Jens Valderrama, Begoña P Kikuchi, Eiji Fléchon, Aude Petrylak, Daniel De Santis, Maria Galsky, Matthew D Lee, Jae Lyun Swami, Umang Sridhar, Srikala S De Giorgi, Ugo Wright, Phoebe Shih, Vanessa Lu, Yi-Tsung Guan, Xuesong Dillon, Ryan Shetty, Aditya Moreno, Blanca Homet Beaumont, Jennifer L Purnajo, Intan McManus, Shauna Powles, Thomas